JABFM
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parnes, B.
Right arrow Articles by Pace, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parnes, B.
Right arrow Articles by Pace, W.
The Journal of the American Board of Family Medicine 19:20-23 (2006)
© 2006 American Board of Family Medicine

Original Research

Provider Deferred Decisions on Hemoglobin A1c Results: A Report from the Colorado Research Network (CaReNet) and the High Plains Research Network (HPRN)

Bennett Parnes, MD, Linda Niebauer, Sherry Holcomb, Miriam Dickinson, PhD, Jack Westfall, MD, Becky VanVorst and Wilson Pace, MD

From the Department of Family Medicine, University of Colorado School of Medicine, Health Sciences Center, Aurora, CO

Correspondence: Corresponding author: Bennett Parnes, Department of Family Medicine, University of Colorado School of Medicine, Health Sciences Center, 12474 E. 19th Avenue, Building 402, PO Box 6508, Campus Box F496, Aurora, CO 80045-0508 (E-mail: bennett.parnes{at}uchsc.edu)

Background: Hemoglobin A1c (HbA1c) results are generally reviewed several days after office visits. The clinical decisions on elevated HbA1cs may be complex and are rarely urgent. Providers may elect to defer the decision or its implementation to a future clinical encounter.

Objective: To determine the occurrence rate, predictors, and eventual decision outcomes for HbA1c deferred decisions.

Design: Provider questionnaire completed when HbA1c results from type 2 diabetes patients were reviewed, followed by a chart review on deferred cases 6 months later.

Participants: Providers at 19 Colorado primary care clinics.

Measurements: For HbA1c ≥7%, whether the decision or its implementation was deferred. In deferred cases, whether a clinical decision was eventually made.

Results: Of the 311 HbA1cs ≥7%, 31 (10.0%) had deferred decisions. In multivariate analysis, deferred decisions were more likely in African Americans (odds ratio [OR] 4.91, 95% CI 1.81, 13.3) and less likely when the patient’s usual provider reviewed the HbA1c (OR 0.40, 95% CI 0.18, 0.90). In the chart review, for deferred cases (n = 18), a clinical decision was made in 14 cases, usually at the next clinical encounter. In 4 cases, the HbA1c was never addressed.

Conclusion: Deferred decisions on HbA1c results are infrequent, and usually the HbA1c is eventually addressed.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Board of Family Medicine.